Merck’s Price Target Cut at Barclays Capital (MRK)

Filed in barclays, Barclays Capital, dividend, Gold Investing, o, revenue, shares, target by on January 24, 2011 0 Comments

Health care giant Merck & Co., Inc. ( MRK ) on Monday saw its price target lowered by analysts at Barclays Capital. The firm said it cut its target for MRK from $43 to $41. That new target still implies a potential 21% upside to the stock’s Friday closing price of $33.90. Barclays also maintained its “Overweight” rating on Merck, but noted the company’s products to be released in 2011 and 2012 won’t add significant revenue upside. Merck shares rose 18 cents, or +0.5%, in premarket trading Monday. The Bottom Line Shares of Merck ( MRK ) have a 4.48% dividend yield, based on Friday’s closing stock price of $33.90. The stock has technical support in the $30-32 price area. If the shares can firm up, we see overhead resistance around the $37 price level. Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

More here:
Merck’s Price Target Cut at Barclays Capital (MRK)

Tags: , , , , , , , , , , ,

About the Author ()

Leave a Reply

Your email address will not be published. Required fields are marked *